Pathogenesis and preclinical course of Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 56, 1999, Pages 31-74

  Foley, P ^a   Riederer, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; BRAIN; BRAIN LEVEL; GENETICS; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BRAIN; BRAIN CHEMISTRY; HUMANS; PARKINSON DISEASE;

EID: 0032588321     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6360-3_2     Document Type: Conference Paper

References (244)

1. Adams JD, Odunze IN (1991) Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Biochem Pharmacol 41: 1099-1105
2. Aime S, Fasano M, Bergamasco B, Lopiano L, Quattrocolo G (1996) Nuclear magnetic resonance spectroscopy characterization and iron content determination of human mesencephalic neuromelanin. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia, pp 263-270
3. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: a selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 69: 1196-1203
4. Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxides and catalase in Parkinson's disease. Arch Neurol 32: 114-118
5. Anglade P, Agid Y, Hirsch EC, Vyas S (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12: 603-610
6. Bancher C, Lassmann H, Budka H, Budka H, Jellinger K, Grundke-Iqbal I, Iqbal K, Wiche G, Seitelberger F, Wisniewski HM (1989) An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 48: 81-93
7. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet II: 1213-1216
8. Baron JA (1986) Cigarette smoking and Parkinson's disease. Neurology 36: 1490-1496
9. Beal MF, Hyman BT, Koroshetz W (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 16: 125-131
10. Beck KD (1994) Functions of brain-derived neurotrophic factor, insulin-like growth factor-I and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons. Prog Neurobiol 44: 497-516
11. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman PA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624
12. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical "Parkinsonism" in rats. J Neurochem 57: 2133-2135
13. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal neurons. J Neurochem 56: 1441-1444
14. Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit: Biochemie, Klinik, Therapie 2nd edn. Springer, Wien New York, pp 60-101
15. Blum-Degen D, Frölich L, Hoyer S, Riederer P (1995) Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm [Suppl] 46: 139-147
16. Blunt SB, Jenner P, Marsden CD (1993) Suppressive effect of 1-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8: 129-133
17. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson's disease. Acta Neuropathol 88: 493-500
18. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RAI, Jansen ENH (1995) Nigral and extranigral pathology in Parkinson's disease. J Neural Transm [Suppl] 46: 15-32
19. Braak, H, Braak E, de Vos RAI, Jansen EHN, Bohl J (1997) Extranigrale Pathologie der Parkinson-Krankheit - limbisches System und vegetative Kerne. In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 25-36
20. Bringmann G, God R, Feineis D, Wesemann W, Riederer P, Rausch WD, Reichmann H, Sontag KH (1995) The TaClo concept: I-trichloromethyl-1,2,3,4-tetrahydro-β-carboline (TaClo), a new toxin for dopaminergic neurons. J Neural Transm [Suppl] 46: 235-244
21. Brookes DJ (1991) Detection of preclinical Parkinson's disease with PET. Neurology 41 (Suppl 2): 24-27
22. Buccala R, Cerami A (1992) Advanced glycosylation: chemistry, biology and implications for diabetes and aging. Adv Pharmacol 23: 1-34
23. Calne DB (1994) Is idiopathic parkinsonism the consequence of an event or a process? Neurology 44: 5-10
24. Calne DB, Eisen AA (1989) The relationship between Alzheimer's disease, Parkinson's disease and motoneuron disease. Can J Neurol Sci 16: 547-550
25. Calne S, Shoenberg BS, Martin W, Uitti RJ, Spencer P, Calne DB (1987) Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 14: 303-315
26. Carlsson A, Fornstedt B (1991) Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease. Neurology 40 (Suppl 2): 50-52
27. Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E (1991) The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097: 152-160
28. Castellani R, Smith MA, Richey PL, Perry G (1996) Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737: 195-200
29. Chandrasekaran K, Rapoport SI, Brady DR, Stoll J (1992) Localization of cytochrome oxidase (COX) activity and COX mRNA in the hippocampus and entorhinal cortex of the monkey brain: correlation with specific neuronal pathways. Brain Res 579: 333-336
30. Chan-Palay V, Zetzsche T, Hochli M (1991) Parvalbumin neurons in the hippocampus in senile dementia of the Alzheimer type, Parkinson's disease and multi-infarct dementia. Dementia 2: 297-313
31. Cleeter MWJ, Cooper JM, Schapira AHV (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 58: 786-789
32. Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AHV (1994) Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: implications for neurodegenerative disorders. Acta Biochem Biophys 288: 481-487
33. Collins MA, Neafsey EJ (1985) β-Carboline analogues of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism. Neurosci Lett 55: 179-184
34. Connor JR, Snyder BS, Arosio P, Loeffler DA, LeWitt P (1995) A quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer's diseased brains. J Neurochem 65: 717-724
35. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262: 689-695
36. D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH (1987) Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327: 324-326
37. Damier P, Hirsch E, Javoy-Agid F, Zhang P, Agid Y (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52: 1-6
38. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1: 249-254
39. Dawson TM, Dawson VL, Snyder SH (1992) A novel neuronal messenger molecule in brain: the free radical, nitric oxide. Ann Neurol 32: 297-311
40. DeLeve LD, Kaplowitz N (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 52: 287-305
41. De Michele G, Filla A, Volpe G, Gogliettino A, Ambrosio G, Campanella G (1996) Etiology of Parkinson's disease. The role of environment and heredity. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia, pp 19-24
42. Dexter DT, Wells FR, Agid FJ (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet II: 1219-1220
43. Dexter DT, Cater CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantial nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
44. Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD (1990) Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55: 16-20
45. Dexter DT, Carayon A, Javoy-Agid F (1991) Alterations in the levels of iron. ferritin and other trace row diroudopically metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114: 1953-1975
46. Dexter DT, Ward RJ, Wells FR, Daniel SE, Lees AJ, Peters IJ, Jenner P, Marsden CD (1992) α-Tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol 32: 591-593
47. Dexter DT, Holley AE, Flitter WD Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1994a) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9: 92-97
48. Dexter DT, Sian J, Rose S, Hindmarsh JS, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AHV, et al (1994b) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35: 38-44
49. Difazio MC, Hollingsworth Z, Young AB, Penney JBJ (1992) Glutamate receptors in the substantia nigra of Parkinson's disease brains. Neurology 42: 402-406
50. DiMonte DA (1991) Mitochondrial DNA and Parkinson's disease. Neurology 41 (Suppl 2): 38-42
51. Dostert P, Strolin-Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntíngton's disease. J Neural Transm 74: 61-74
52. Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38: 1237-1244
53. Double KL, Halliday GM, McRitchie DA, Reid WGJ, Hely MA, Morris JGL (1996) Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease. Dementia 7: 304-313
54. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M (1997) In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 70: 2492-2499
55. Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J Neuropathol Exp Neurol 24: 398-414
56. Duvoisin RC (1996) Recent advances in the genetics of Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia, pp 33-40
57. Fahn S (1992) Adverse effects of levodopa. In: Olanow CW, Lieberman AN (eds) The scientific basis for the treatment of Parkinson's disease. Parthenon, Carnforth (UK), pp 89-112
58. 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 60: 2238-2241
59. Faucheaux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, Agid Y, Hirsch EC (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc Natl Acad Sci USA 92: 9303-9307
60. Fawthrop DJ, Boobis AR, Davies DS (1991) Mechanisms of cell death. Arch Toxicol 65: 437-444
61. Fearnley JM, Lees A (1991) Ageing and Parkinson's disease: substantia nigra regional seletivity. Brain 114: 2283-2301
62. Fornai F, Vaglini F, Maggio R, Bonuccelli U, Corsini GU (1996) Excitatory amino acids and MPTP toxicity. In: Battistin L, Scarlato O, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia, pp 167-176
63. Forno LS (1995) Pathological considerations in the etiology of Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson's disease. Marcel Dekker, New York, pp 65-95
64. Forno LS, Langston JW (1993) Lewy bodies and aging: relation to Alzheimer's and Parkinson's diseases. Neurodegeneration 2: 19-24
65. Forno LS, DeLanney LE, Irwin I, Langson JW (1995) Ultrastructure of eosinophilic inclusion bodies in the amygdala-parahippocampal region of aged squirrel monkeys treated with 1-melhyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic toxin. Neurosci Lett 184: 44-47
66. Forno LS, DeLanney LE, Irwin I, Langson JW (1996) Electron microscopy of Lewy bodies in the amygdala-parahippocampal region: comparison with inclusion bodies in the MPTP-treated squirrel monkey. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology, vol 53, Parkinson's disease: anatomy, pathology and therapy. Raven Press, New York, pp 217-228
67. Franklin JL, Johnson EM (1992) Suppression of programmed neuronal cell death by sustained elevation of cytosolic calcium. Trends Neurosci 15: 501-508
68. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255
69. Gasser T (1997) Stand der neurogenetischen Forschung bezüglich der Parkinson-Erkrankung. In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 59-71
70. Gasser T, Wszolek ZK, Trofatter J, Ozelius L, Uitti RJ, Lee CS, Gusella J, Pfeiffer RF, Calne DB, Breakefield XO (1994) Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 36: 387-396
71. Gerlach M, Riederer P (1993) The pathophysiological basis of Parkinson's disease. In: Szelenyi (ed) Inhibitors of monoamine oxidase. Birkhäuser, Basel, pp 25-50
72. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103: 987-1041
73. Gerlach M, Riederer P, Przuntek H, Youdim MBH (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol [Mol Pharmacol Sect] 208: 273-286
74. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-807
75. Gerlach M, Riederer P, Youdim MBH (1996) Molecular mechanisms for neurodegeneration: synergism between reactive oxygen species, calcium and excitotoxic amino acids. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia, pp 177-194
76. German DC, Manaye KF, Sonsalla PK, Brooks BA (1992) Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin D28k-containing cells. Ann NY Acad Sci 648: 42-62
77. Gibb WRG (1989) The diagnostic relevance of Lewy bodies and other inclusions in Parkinson's disease. In: Przuntek H, Riederer P (eds) Early diagnosis and preventative therapy in Parkinson's disease. Springer, Wien New York, pp 171-180
78. Gibb WRG (1992) Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 581: 283-291
79. Gibb WRG, Lees AJ (1989) The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 15: 27-44
80. Gibb WRG, Esiri MM, Lees AJ (1985) Clinical and pathologic features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 110: 1131-1153
81. Gibb WRG, Scott T, Lees AJ (1991) Neuronal inclusions of Parkinson's disease. Mov Disord 6: 2-11
82. Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress. Free radical production in neural degeneration. Pharmac Ther 63: 37-122
83. Golbe LI (1995) Genetics of Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson's disease. Marcel Dekker, New York, pp 115-140
84. Golbe LI, Lazzarini AM, Schwarz KO, Mark MH, Dickson DW, Duvoison RC (1993) Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology 43: 2222-2227
85. Goldman JE, Yen SH, Chiu FC, Peress NS (1983) Lewy bodies of Parkinson's disease contain neurofilament antigen. Science 221: 1082-1084
86. Good P, Olanow CW, Perl DP (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease. A LAMMA study. Brain Res 593: 343-346
87. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643
88. Greenlund LJ, Deckwerth TL, Johnson EMJ (1995) Superoxide dismutase delays neuronal aptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 14: 303-315
89. Grote C, Clement HW, Wesemann W, Bringmann G, Feineis D, Riederer P, Sontag KH (1995) Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline) and derivatives. J Neural Transm [Suppl] 46: 275-281
90. Gutteridge JM, Quinlan GJ, Clark I, Halliwell B (1985) Aluminum salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta 835: 441-447
91. Halliday GM, Blumberg PC, Cotton RGH, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 510: 104-107
92. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623
93. Hansen LA, Galasko D (1992) Lewy body disease. Curr Opin Neurol Neurosurg 5: 889-894
94. Hattori N, Tanaka M, Ozawa T, Mizuno Y (1991) Immunohistochemical studies on complexes I, II, III and IV of mitochondria in Parkinson's disease. Ann Neurol 30: 563-571
95. Hefti F (1994) Neurotrophic factor therapy for central nervous system degenerative disease. J Neurobiol 25: 1418-1435
96. Hefti F, Melamed E, Bhawan J, Wurtman R (1981) Long term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 31: 1194-1195
97. Heintz N, Zoghbi H (1997) α-synuclein - a link between Parkinson and Alzheimer diseases? Nat Genet 16: 325-327
98. Hill W, Lee VMY, Hurtig H, Murray JM, Trojanowski JQ (1991) Epitopes located in spatially separated domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol 309: 150-160
99. Hirsch EC, Graybiel AM, Agid Y (1988) Melanized dopaminergic neurons are differentially affected in Parkinson's disease. Nature 334: 345-348
100. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56: 446-451
101. 28K-like immunoreactivity in catecholaminergic cell groups in the human midbrain. Normal distribution and distribution in Parkinson's disease. Neurodegeneration 1: 83-93
102. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y (1997) Neuronal vulnerability in Parkinson's disease. J Neural Transm [Suppl] 50: 79-88
103. Hotamisligil GS, Girmen AS, Fink JS, Tivol E, Shalish C, Trofatter J, Baenziger J, Diamond S, Markham C, Sullivan J, et al (1994) Hereditary variations in the monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 9: 305-310
104. Hunot S, Boissièrre F, Faucheux B, Brugg B, Mouatt-Prigend A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355-363
105. Iacopino AM, Christakos S (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 87: 4078-4082
106. 28k-immunoreactive cholinergic neurons in the nucleus basalis of Meynert in Alzheimer-type dementia. Brain Res 499: 402-406
107. Ikonomidou C, Turski L (1996) Neurodegenerative disorders: clues from glutamate and energy metabolism. Crit Rev Neurobiol 10: 239-263
108. Irwin I, Langston JW (1995) Endogenous toxins as potential etiologic agents in Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson's disease. Marcel Dekker, New York, pp 153-201
109. Itoh K, Weis S, Mehracin P, Muller-Hocker J (1997) Defects of cytochrome c oxidase in the substantia nigra of Parkinson's disease: an immunohistochemical and morphometric study. Mov Disord 12: 9-16
110. Janetzky B, God R, Bringmann G, Reichmann H (1995) 1-Trichloromethyl-1,2,3,4-tetrahydro-β-carboline, a new inhibitor of complex I. J Neural Transm [Suppl] 46: 265-273
111. Jellinger KA (1990) New developments in the pathology of Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds) Advances in neurology, vol 53, Parkinson's disease: anatomy, pathology and therapy. Raven Press, New York, pp 1-16
112. Jellinger KA (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14: 153-197
113. Jellinger KA (1995) Neurodegenerative disorders with extrapyramidal features. J Neural Transm [Suppl] 46: 33-58
114. Jellinger P, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson's disease and Alzheimer's diseases. J Neural Transm [PD Sect] 2: 327-340
115. Jellinger K, Youdim MBH, Ben-Shachar D, Stachelberger H, Riederer P, Rumpelmair G, Kienzl E (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168-1171
116. Jellinger K, Linert L, Kienzl E, Youdim MBH (1995) Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm 46: 297-314
117. Jenner P, Olanow CW (1996a) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 [Suppl 3]: S161-S170
118. Jenner P, Olanow CW (1996b) Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim M (eds) Neurodegeneration and neuroprotection in Parkinson's disease. Academic Press, London, pp 24-45
119. Johnson WG, Hodge SE, Duvoisin RC (1990) Twin studies and the genetics of Parkinson's disease - a reappraisal. Mov Disord 5: 187-194
120. Kass GEN, Wright JM, Nicotera P, Orrenius S (1988) The mechanism of 1-melhyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. Arch Biochem Biophys 260: 789-797
121. Kish SJ, Morito CH, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58: 343-346
122. Klockgether T, Turski L (1993) Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann Neurol 34: 585-593
123. Koller WC, Montgomery EB (1997) Issues in the early diagnosis of Parkinson's disease. Neurology 49 [Suppl 1]: S10-S25
124. Kondo K, Kurland RT (1973) Parkinson's disease, genetic analysis and evidence of a multifactorial etiology. Mayo Clin Proc 48: 465-474
125. Kosaka K (1978) Lewy bodies in the cerebral cortex: report of three cases. Acta Neuropathol (Berl) 42: 127-134
126. Kosel S, Lucking SB, Egensperger R, Mehraein P, Graeber MB (1996) Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. J Neurosci Res 44: 174-183
127. Kuhn W, Müller T (1995) Neuroimmune mechanisms in Parkinson's disease. J Neural Transm [Suppl] 46: 229-234
128. Kuhn W, Müller T (1997) Hypersusceptibilität gegen Xenobiotika. Die potentielle Bedeutung ökogenetischer Faktoren für die Âtiologie des Morbus Parkinson. In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 87-93
129. Kuhn W, Müller T, Große H, Rommelspacher H (1995) Plasma harman and norharman in Parkinson's disease. J Neural Transm [Suppl] 46: 291-295
130. Kupsch A, Oertel WH, Earl CD, Sautter J (1995) Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease - update February 1995. J Neural Transm [Suppl] 46: 193-207
131. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD (1993) Association of a monoamine oxidase B allele with Parkinson's disease. Neurology 33: 368-372
132. Landfield PW, Applegate MD, Schwitzer-Osborne SE, Naylor CE (1991) Phosphate/ calcium alterations in the first stages of Alzheimer's disease: Implications for etiology and pathogenesis. J Neurol Sci 106: 221-229
133. Landi MT, Ceroni M, Martignoni E, Bertazzi PA, Caporaso NE, Nappi G (1996) Gene-environment action in Parkinson's disease. The case of CYP2D6 polymorphism. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia, pp 61-72
134. Langston JW (1996) The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47 [Suppl 3]: S153-S160
135. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 970-980
136. Lazzarini AM, Myers RH, Zimmerman TR, Mark MH, Golbe JI, Sage JI, Johnson WG, Duvoisin RC (1994) A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 44: 499-506
137. Lee CS, Schulzer M, Mak E, Snow BJ, Tsui JK, Calne S, Hammerstad J, Calne B (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117: 501-507
138. Leigh P, Probst A, Gale G, Dale GE, Power DP, Brion JP, Dodson A, Anderton BH (1989) New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies. Acta Neuropathol (Berl) 79: 61-72
139. Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, Agid Y, Hof PR (1996) Immunohistochemical analysis of the iron binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 91: 566-572
140. Lewy FH (1912) Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M (ed) Handbuch der Neurologie, vol III. Springer, Berlin, pp 920-933
141. Lindquist NG, Larsson BS, Lyden-Sokolowski A (1987) Neuromelanin and its possible protective and destructive properties. Pigment Cell Res: 133-136
142. Mann DMA, Yates PO (1983) Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Age Dev 21: 193-203
143. Mann DMA, Yates PO, Barton CM (1977) Neuromelanin and RNA in cells of substantia nigra. J Neuropathol Exp Neurol 36: 379-383
144. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH (1994) Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36: 876-881
145. Maraganore DM, Harding AE, Marsden CD (1991) A clinical and genetic study of familial Parkinson's disease. Mov Disord 6: 205-211
146. Marklund S, Adolfsson R, Gottfries C, Winblad B (1985) Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J Neurol Sci 67: 319-325
147. Marsden CD (1983) Neuromelanin and Parkinson's disease. J Neural Transm [Suppl] 19: 121-141
148. Martilla RJ, Rinne UK (1981) Epidemiology of Parkinson's disease: an overview. J Neural Transm 51: 135-148
149. Martilla RJ, Lorentz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson's disease: increase of superoxide dismutase-like activity in the substantial nigra and basal nucleus. J Neurol Sci 86: 321-331
150. Matsubara K, Koyabashi S, Koyabashi Y, Yamashita K, Koide H, Hatta M, Iwamoto K, Tanaka O, Kimura K (1995) β-Carbolinium cations, endogenous MPP analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 45: 2240-2245
151. McCall T, Vallance P (1991) Nitric oxide takes center stage with newly defined roles. Trends Pharmacol Sci 13: 1-6
152. McGeer PL, Itagaki S, Akiyama K, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24: 574-576
153. Miller DM, Buettner GR, Aust SD (1990) Transition metals as catalysts of auto-oxidation reactions. Free Radical Biol Med 8: 95-108
154. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe SI (1994) An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 35: 204-210
155. Mjönes H (1949) Paralysis agitans: a clinical and genetic study. Acta Psychiatr Neurol 54: 1-95
156. Mochizuki H, Goto K, Mori H, Mizuno Y (1996) Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 137: 120-123
157. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, Nagatsu T (1996) The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 220: 195-198
158. Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG, Hirayama K (1994) Loss of insukin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol 87: 343-348
159. 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 119: 585-591
160. Mouant-Prigent A, Karlsson JO, Agid Y, Hirsch EC (1996) Increased m-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in cell death? Neuroscience 73: 979-987
161. Münch G, Thome J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation end products in ageing and disease. Brain Res Rev 23: 134-143
162. Mufson EJ, Brandabur MM (1994) Sparing of NADPH-diaphorase striatal neurons in Parkinson's and Alzheimer's diseases. Neuroreport 5: 705-708
163. 3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease. Brain Res 377: 186-189
164. Nussbaum RL, Polymeropoulos MH (1997) Genetics of Parkinson's disease. Hum Mol Genet 6: 1687-1691
165. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash G (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron in within the substantia nigra: a histochemical and neurochemical study. Brain Res 660: 8-18
166. Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E (1997) Dopamine-melanin induces apoptosis in PC12 cells: possible implications for etiology of Parkinson's disease. Neurochem Int 31: 207-216
167. Olanow CW (1997) Attempts to obtain neuroprotection in Parkinson's disease. Neurology 49 [Suppl 1]: S26-S33
168. Olney JW (1978) Neurotoxicity of excitatory amino acids. In: McGeer EG, Olney JW (eds) Kainic acid as a tool in neurobiology. Raven, New York, pp 95-121
169. Olney JW (1989) Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26: 505-525
170. Olson L (1997) The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications. Trends Neurosci 20: 277-279
171. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755
172. Pearce RKB, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104: 661-677
173. Perry TL, Goden DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 33: 305-310
174. Perry TL, Young VW, Ito M, Foulks JG, Wall RA, Godin DV, Clavier RM (1984) Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 43: 990-993
175. Perry RH, Irving D, Tomlinson BE (1990) Lewy body prevalence in the aging brain: relationship to neuropsychiatrie disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 100: 223-233 (published erratum in J Neural Sci (1991) 102:121)
176. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslovv JW (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzhwimer's disease. Neuron 7: 695-702
177. 3H]Nitrendipine binding in temporal cortex in Alzheimer's and Huntington's diseases. Brain Res 565: 42-47
178. Pilas B, Sarna T, Kalyanaraman B, Swartz RM (1988) The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radical Biol Med 4: 285-293
179. Pileblad E, Magnusson T, Fornstedt B (1996) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J Neurochem 52: 978-980
180. Poewe W, Gerstenbrand F, Ransmayr G, Plorer S (1983) Premorbid personality of Parkinsonian patients. J Neural Transm [Suppl] 19: 215-224
181. Polymeropoulos MH, Lowedern C, Leroy E, Ide SE, Dehija A, Dutra A, Pike B, Root H, Kubenstein J, Boyer R, et al (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047
182. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S,
183. Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini AB, Fahn S (1993) Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34: 715-723
184. Przuntek H, Müller T, Kuhn W, Hoffmann V (1997) Ist Apoptose, ein zentraler Mechanismus der Neurodegeneration, durch Selegiline beeinflußbar? In: Fischer PA (ed) Parkinson-Krankheit. Entwicklungen in Diagnostik und Therapie. Schattauer, Stuttgart, pp 259-274
185. Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite-induced membrane peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288: 481-487
186. Reichmann H, Lestienne P, Jellinger K, Riederer P (1993) Parkinson's disease and the electron transport chain in post mortem brain. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in neurology, vol 60, Parkinson's disease: from basic research to treatment. Raven, New York, pp 297-299
187. Reif DW, Simmons RD (1990) Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 283: 537-541
188. Riederer P, Youdim MBH (eds) (1993) Iron in central nervous system disorders. Springer, Wien New York
189. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease: a detailed study of influential factors in human brain amine analogues. J Neural Transm [P-D Sect] 38: 277-301
190. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52: 515-520
191. Rinne JO, Halonen T, Rickinnen PJ, Rinne UK (1988) Free amino acids in the brain of patients with Parkinson's disease. Neurosci Lett 94: 182-186
192. Robbins JH, Otsuka F, Nee LE (1985) Parkinson's disease and Alzheimer's disease: hypersensitivity to x-rays in cultured cell lines. J Neurol Neurosurg Psychiatry 48: 916-923
193. Román GC, Zhang ZX, Ellenberg JH (1995) The neuroepidemiology of Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson's disease. Marcel Dekker, New York, pp 203-243
194. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al (1993) Mutations in Cu/Zn superoxide dísmutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62 (published erratum: Nature 364: 362)
195. Rubanyi GM, Ho EH, Cantor EH, Lumma WC, Botelho LH (1991) Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 181: 1392-1397
196. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsen CD (1989) A selective increase in particulate supcroxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 53: 692-697
197. Sanchez-Ramos JR, Övervik E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3: 197-204
198. 18F]dopa positron emission tomography studies in an Irish kindred. Ann Neurol 32: 609-617
199. Schapira AHV (1994) Evidence for mitochondrial dysfunction in Parkinson's disease -a critical appraisal. Mov Disord 9: 125-13
200. Schapira AHV (1996) Neurotoxicity and the mechanisms of cell death in Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia, pp 161-165
201. Schapira AHV (1997) Mitochondrial disorders. Curr Opin Neurol 10: 43-47
202. Schapira AHV, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55: 2142-2145
203. Scherman D, Desnos C, Darchen F, Javoy-Agid F, Agid Y (1989) Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 26: 551-557
204. Seaton TA, Marsden CD, Jenner P (1996) Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. Biochem Pharmacol 13: 1657-1663
205. Sen AP, Boksa P, Quirion R (1993) Brain calcium channel-related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases. Brain Res 611: 216-221
206. Sengstock GJ, Olanow CW, Dunn AJ, Arendash GW (1992) Iron induces degeneration of nigrostriatal neurons. Brain Res Bull 28: 645-649
207. Sengstock GJ, Olanow CW, Dunn AJ, Barone S, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume and rotational behavior following iron infusion into rat substantia nigra. Exp Neurol 130: 82-94
208. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36: 356-361
209. Siesjö BK (1990) Calcium in the brain under physiological and pathological conditions. Eur Neurol 30: 3-9
210. Singer TP, Castagnoli N, Ramsay RR, Trevor AJ (1987) Biochemical events in the development of parkinsonism induced by of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49: 1-8
211. Smith TA, Prayson RA (1996) Lewy body disease. South Med J 89: 1174-1180
212. Snow BJ (1996) Fluorodopa PET scanning in Parkinson's disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69, Parkinson's disease. Lippincott-Raven, Philadelphia. pp 449-457
213. Sofic E, Riederer P, Heinsen H, Beckman H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron(III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J Neural Transm 74: 199-205
214. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142: 128-130
215. Sontag KH, Heim C, Sontag TA, God R, Reichmann H, Wesemann W, Rausch WD, Riederer, Bringmann G (1995) Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline) after subchronic treatment in rats. J Neural Transm [Suppl] 46: 283-289
216. Spencer PS, Butterfield PG (1995) Environmental agents and Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW (eds) Etiology of Parkinson's disease. Marcel Dekker, New York, pp 319-365
217. Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC (1987) Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237: 517-522
218. Spencer JPE, Jenner A, Aruoma OI, Evans PJ, Kaur H, Dexter DT, Jenner P, Lees AJ, Marsden DC, Halliwell B (1994) Intense oxidative DNA damage promoted by 1-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 353: 246-250
219. Spencer-Smith T, Parker WD, Bennett JP (1994) L-Dopa increases nigral production of hydroxyl radicals in vivo: potential 1-dopa toxicity? Neuroreport 5: 1009-1011
220. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) α-synuclein in Lewy bodies (letter). Nature 388: 839-840
221. Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 88: 1398-1400
222. Springer JE, Mu X, Bergmann LW, Trojanowsky Q (1994) Expression of GDNF mRNA in rat and human nervous tissue. Exp Neurol 127: 167-170
223. Swan GA (1963) Chemical structure of melanins. Ann NY Acad Sci 100: 1005
224. Swartz HM, Sarna T, Zecca L (1992) Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol 32 [Suppl]: S69-S75
225. Taussig D, Plante-Bordeneuve V (1997) Les syndromes parkinsoniens familiaux "atypiques". Maladies de Parkinson ou entites autonomes? Presse Med 26: 290-296
226. Temlet JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 62: 134-146
227. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61: 1191-1206
228. Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD (1997) Chronic glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm [PD Sect] 104: 67-75
229. Tomac A, Lindquist E, Lin LFH, Ögren SO, Young D, Hoffer BJ, Olsen L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339
230. Tompkins MM, Basgall EJ, Zamrini E, Hill WD (1997) Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 150: 119-131
231. Tooyama I, Kawamata T, Walker D, Yamada I, Hanai K, Kimura H, Iwane M, Igarashi K, McGeer EG, McGeer PL (1993) Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 43: 372-376
232. 1 neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349: 414-418
233. Vieregge P (1994) Genetic factors in the etiology of Parkinson's disease. J Neural Transm 8: 1-37
234. Walinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-dopa; imolications for the treatment of Parkinson's disease. J Clin Invest 95: 2458-2464
235. Wallace DC (1992a) Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256: 628-632
236. Wallace DC (1992b) Diseases of the mitochondrial DNA Ann Rev Biochem 61: 1175-1212
237. Waters CH, Miller CA (1994) Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 35: 59-64
238. Wesemann W, Blaschke S, Solbach M, Grote C, Clement HW, Riederer P (1994) Intranigral injected iron progressively reduces striatal dopamine metabolism. J Neural Transm [PD Sect] 8: 209-214
239. Wüllner U, Löschmann PA, Schulz JB, Schmid A, Dringen R, Eblen F, Turski L, Klockgether T (1996) Glutathione depletion potentiates MPTP and MPP toxicity in nigral dopaminergic neurones. Neuroreport 7: 921-923
240. Yamada T, McGeer PL, Baimbridge KG, McGeer EG (1990) Relative sparing in Parkinson's disease of substantia nigra neurons containing calbindin D28K. Brain Res 526: 303-307
241. Yen TC, Chen YS, King KL, Yeh SH, Wei YH (1989) Liver mitochondrial functions decline with age. Biochem Biophys Res Commun 165: 994-1003
242. Yoritaki A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc Natl Acad Sci USA 93: 2696-2713
243. Yoshida E, Mokuno K, Aoki SI, Takahashi A, Riku S, Murayama T, Yanagi T, Kato K (1994) Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 124: 25-31
244. Youdim MBH, Ben-Shachar D, Riederer P (1994) The enigma of neuromelanin in Parkinson's disease substantia nigra. J Neural Transm [Suppl] 43: 113-132